Log In
BCIQ
Print this Print this
 

darinaparsin (SP-02, SP-02L, ZIO-101)

  Manage Alerts
Collapse Summary General Information
Company Ziopharm Oncology Inc.
DescriptionIV formulation of organic arsenic
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationT cell lymphoma
Indication DetailsTreat peripheral T cell lymphoma (PTCL); Treat relapsed and refractory peripheral T cell lymphoma (PTCL)
Regulatory Designation U.S. - Orphan Drug (Treat peripheral T cell lymphoma (PTCL));
EU - Orphan Drug (Treat peripheral T cell lymphoma (PTCL))
PartnerMeiji Seika Pharma Co. Ltd.;
Solasia Pharma K.K.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$91.0M

$5.0M

$86.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

01/19/2015

Undisclosed

Undisclosed

Undisclosed

03/07/2011

$91.0M

$5.0M

$86.0M

Get a free BioCentury trial today